Many clinical studies have demonstrated that low-dose IL-2 ranging from 0.3 × 106 to 3.0 × 106 IU improved chronic inflammatory states and outcomes in patients with type 1 diabetes, ischemic heart disease, autoimmune liver disease, and lupus [10,11,12,13]. Here, IL2 is linked to systemic lupus erythematosus.